Literature DB >> 35175470

Genetic Markers of Therapeutic Efficacy of Methotrexate in Patients with Psoriasis.

O E Voron'ko1, K K Baskaev1, V V Sobolev2,3, E V Denisova4, I M Korsunskaya4.   

Abstract

We studied the effect of C677T and A1298C polymorphisms of the MTHFR gene and 2R/3R polymorphisms of the TYMS gene on the sensitivity to methotrexate in patients with psoriasis (n=139). It was shown that genotype 3R/3R TYMS (OR 8.86, 95%CI 2.00-39.22) and complex genotypes MTHFR1298:A;TYMS:3R (OR 8.20, 95%CI 2.36-28.48) and MTHFR677:C;TYMS:3R (OR 5.40, 95%CI 1.95-14.94) were associated with sensitivity to methotrexate, while genotype 2R/2R TYMS (OR 8.20, 95%CI 2.36-28.48) and complex genotypes MTHFR1298:C;MTHFR677:T;TYMS:2R (OR 0.18, 95%CI 0.06-0.56) and MTHFR1298:C;MTHFR677:T (OR 0.23, 95%CI 0.09-0.59) were associated with resistance to methotrexate. The results can be used for preventive assessment of the effectiveness of methotrexate treatment in patients with psoriasis.
© 2022. Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  genetic markers; methotrexate; methylenetetrahydrofolate reductase (MTHFR); psoriasis; thymidylate synthase

Mesh：

Substances：

Year:  2022        PMID： 35175470     DOI： 10.1007/s10517-022-05413-6

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN： 0007-4888            Impact factor:   0.804


  11 in total

1.  The C677T mutation in the methylenetetrahydrofolate reductase gene: a genetic risk factor for methotrexate-related elevation of liver enzymes in rheumatoid arthritis patients.

Authors:  A E van Ede; R F Laan; H J Blom; T W Huizinga; C J Haagsma; B A Giesendorf; T M de Boo; L B van de Putte
Journal:  Arthritis Rheum       Date:  2001-11

2.  Polymorphisms in the thymidylate synthase and methylenetetrahydrofolate reductase genes and sensitivity to the low-dose methotrexate therapy in patients with rheumatoid arthritis.

Authors:  Kazuhiko Kumagai; Keiko Hiyama; Tetsu Oyama; Hiroyuki Maeda; Nobuoki Kohno
Journal:  Int J Mol Med       Date:  2003-05       Impact factor: 4.101

3.  Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes.

Authors:  Judith A M Wessels; Jeska K de Vries-Bouwstra; Bas T Heijmans; P Eline Slagboom; Yvonne P M Goekoop-Ruiterman; Cornelia F Allaart; Pit J S M Kerstens; Derkjen van Zeben; Ferdinand C Breedveld; Ben A C Dijkmans; Tom W J Huizinga; Henk-Jan Guchelaar
Journal:  Arthritis Rheum       Date:  2006-04

4.  Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses.

Authors:  Wako Urano; Atsuo Taniguchi; Hisashi Yamanaka; Eiichi Tanaka; Hiroshi Nakajima; Yuko Matsuda; Hideto Akama; Yutaka Kitamura; Naoyuki Kamatani
Journal:  Pharmacogenetics       Date:  2002-04

5.  Methylenetetrahydrofolate reductase polymorphisms, C677T and A1298C, are associated with methotrexate-related toxicities in Korean patients with rheumatoid arthritis.

Authors:  Jung-Yoon Choe; Hwajeong Lee; Hyun-Young Jung; Sung-Hoon Park; Sang-Cheol Bae; Seong-Kyu Kim
Journal:  Rheumatol Int       Date:  2011-07-21       Impact factor: 2.631

6.  Polymorphisms C677T and A1298C in the MTHFR gene in Mexican patients with rheumatoid arthritis treated with methotrexate: implication with elevation of transaminases.

Authors:  J P Mena; M Salazar-Páramo; L González-López; J I Gámez-Nava; L Sandoval-Ramirez; J D Sánchez; L E Figuera; F J Muñoz-Valle; M Vazquez del Mercado; I P Dávalos
Journal:  Pharmacogenomics J       Date:  2010-06-01       Impact factor: 3.550

7.  Pharmacogenetic polymorphisms contributing to toxicity induced by methotrexate in the southern Spanish population with rheumatoid arthritis.

Authors:  José Cristian Plaza-Plaza; Margarita Aguilera; Marisa Cañadas-Garre; Clarice Chemello; Alfonso González-Utrilla; María José Faus Dader; Miguel Angel Calleja
Journal:  OMICS       Date:  2012-10-24

8.  Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis.

Authors:  Prabha Ranganathan; Robert Culverhouse; Sharon Marsh; Ami Mody; Tiffany J Scott-Horton; Richard Brasington; Amy Joseph; Virginia Reddy; Seth Eisen; Howard L McLeod
Journal:  J Rheumatol       Date:  2008-03-15       Impact factor: 4.666

9.  Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism.

Authors:  Petra Bohanec Grabar; Dusan Logar; Boris Lestan; Vita Dolzan
Journal:  Eur J Clin Pharmacol       Date:  2008-07-08       Impact factor: 2.953

10.  TYMS polymorphisms and responsiveness to or toxicity of methotrexate in rheumatoid arthritis.

Authors:  Sang-Cheol Bae; Young Ho Lee
Journal:  Z Rheumatol       Date:  2018-11       Impact factor: 1.372
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.